NCT01109017View on ClinicalTrials.gov

Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency

CompletedOBSERVATIONAL
Enrollment

387

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Growth Hormone DisorderAdult Growth Hormone Deficiency
Interventions
DRUG

somatropin

Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.

Trial Locations (1)

1000005

Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY